Biomerica (NASDAQ:BMRA) issued its earnings results on Thursday. The company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.06), Fidelity Earnings reports. Biomerica had a negative net margin of 34.95% and a negative return on equity of 36.23%.
BMRA opened at $7.29 on Friday. The business’s 50 day moving average is $7.14 and its 200-day moving average is $7.53. The stock has a market cap of $85.68 million, a PE ratio of -31.70 and a beta of -0.83. Biomerica has a twelve month low of $2.05 and a twelve month high of $23.39.
Separately, Aegis lifted their target price on Biomerica from $10.00 to $13.00 and gave the company a “buy” rating in a research note on Friday, September 4th.
Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.
Featured Story: What type of investment options does a Roth IRA provide?
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.